Keyword: Bone Therapeutics
The data committee ruled Preob is unlikely to improve outcomes in patients with osteonecrosis, wiping 25% off Bone Therapeutics’ stock price.
Bone wants to move the therapy into phase 2b, but that plan is on hold as it adopts an industrialized manufacturing process.
Bristol-Myers tapped Thomas Lynch as new CSO, Karaboutis joined a long list of execs who had left Biogen, and Editas bid farewell to its very first employee and COO Glucksmann.
Teva promotes David Stark to chief legal officer amid DOJ's investigation of price fixing, Terrance Coughlin was named EVP and COO of Endo, and Neon Therapeutics recruits former Eli Lilly vet Dr. Richard Gaynor as new CMO. Plus more hirings, firings and retirings throughout the industry.
Bone Therapeutics has scrapped plans to trial its autologous cell therapy Preob in the U.S.
Allergan International’s former head Paul Navarre to lead Nestlé Skin Health, Boston Scientific hires veteran cardiologist Prof. Ian Meredith as EVP and CMO, and Enrico Bastianelli steps down as CEO of Bone Therapeutics. Plus more hirings, firings and retirings throughout the industry.
Enrico Bastianelli is stepping down as CEO of Bone Therapeutics after 10 years, leaving a former Eli Lilly and Lundbeck commercial director in charge.
Bone Therapeutics has posted an interim look at data from a small Phase IIa trial of its allogeneic cell therapy in lumbar spinal fusion.
